Neuropathic Pain Program
Neuropathic Pain
PreclinicalActive
Key Facts
About VersaPeutics
VersaPeutics is a private, pre-revenue biotech startup founded in 2016, targeting significant challenges in neuroscience. The company is in the early stages of building its scientific team and research programs, with a focus on translating recent breakthroughs in neuroscience into novel therapeutics. Its initial pipeline aims at Alzheimer's disease, spinal cord injury, and neuropathic pain, representing areas with substantial market need and limited treatment options. As a nascent company, its near-term goals are centered on securing investment, advancing its research platform, and progressing its lead candidates toward the clinic.
View full company profileTherapeutic Areas
Other Neuropathic Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Peripheral nerve pain agent | Nyrada | Preclinical |
| NTRX-07 | NeuroTherapia | Pre-clinical |
| Neuropathic Pain Model Service | NeuroProof | Pre-clinical |
| Sana Device for Neuropathic Pain | Sana Health | Pivotal Trial Completed |
| Cerebro Platform for Pain | Vonova.io | Pre-clinical |
| LAT9997 | Lateral Pharma | Phase 2 (next-gen) |
| ZYNPN | Zyneyro | Pre-clinical |
| XT-150 (Preclinical) | Xalud Therapeutics | Preclinical |
| ONO-2910 | Ono Pharmaceutical | Phase 2 |
| VX-548 | Vertex Pharmaceuticals | Phase 2 |
| BDT272 | KYORIN Pharmaceutical | Preclinical |
| HSK16149 | Haisco Pharmaceutical Group | Phase III |